Shares of Zoetis dropped more than 7% in trading on April 12 following a Wall Street Journal article highlighting how health regulators in the U.S. and Europe have received thousands of complaints about the animal health company’s arthritis drugs Librela and Solensia due to negative side effects.
Contact our attorneys for a no-cost case evaluation.